Next Article in Journal
A Rare Pediatric Case of Severe Bird Fancier’s Lung Presented with Viral Pneumonitis-Like Picture
Next Article in Special Issue
Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy
Previous Article in Journal
Gamma Glutamyl Transferase and Uric Acid Levels Can Be Associated with the Prognosis of Patients in the Pediatric Intensive Care Unit
Previous Article in Special Issue
Molecularly Targeted Therapy for Neuroblastoma
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessReview
Children 2018, 5(11), 148;

Novel Therapies for Relapsed and Refractory Neuroblastoma

Department of Pediatrics, Division of Hematology-Oncology, University of California San Diego, La Jolla, CA 92093, USA
Peckham Center for Cancer and Blood Disorders, Rady Children’s Hospital, San Diego, CA 92123, USA
Received: 11 September 2018 / Revised: 23 October 2018 / Accepted: 23 October 2018 / Published: 31 October 2018
(This article belongs to the Special Issue Recent Advances in Diagnosis and Treatment of Neuroblastoma)
PDF [292 KB, uploaded 31 October 2018]


While recent increases in our understanding of the biology of neuroblastoma have allowed for more precise risk stratification and improved outcomes for many patients, children with high-risk neuroblastoma continue to suffer from frequent disease relapse, and despite recent advances in our understanding of neuroblastoma pathogenesis, the outcomes for children with relapsed neuroblastoma remain poor. These children with relapsed neuroblastoma, therefore, continue to need novel treatment strategies based on a better understanding of neuroblastoma biology to improve outcomes. The discovery of new tumor targets and the development of novel antibody- and cell-mediated immunotherapy agents have led to a large number of clinical trials for children with relapsed neuroblastoma, and additional clinical trials using molecular and genetic tumor profiling to target tumor-specific aberrations are ongoing. Combinations of these new therapeutic modalities with current treatment regimens will likely be needed to improve the outcomes of children with relapsed and refractory neuroblastoma. View Full-Text
Keywords: neuroblastoma; relapsed neuroblastoma; recurrent neuroblastoma; refractory neuroblastoma; personalized treatment; ALK; RET; MIBG; retinoic acid neuroblastoma; relapsed neuroblastoma; recurrent neuroblastoma; refractory neuroblastoma; personalized treatment; ALK; RET; MIBG; retinoic acid
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Zage, P.E. Novel Therapies for Relapsed and Refractory Neuroblastoma. Children 2018, 5, 148.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Children EISSN 2227-9067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top